Market
The Hague court finds infringement of Halozyme patent Concerns grow over platform expansion and royalty timing

A Dutch court has found that Merck & Co.’s (MSD) subcutaneous (SC) formulation of Keytruda infringes a European patent held by Halozyme and has banned its manufacture, sale and import in eight European countries.
The ruling that ALT-B4, a human hyaluronidase platform technology that Alteogen has emphasized it developed independently, infringes a competitor’s patent has heightened concerns about the platform’s global expansion and the timing of royalty revenue.
The District Court of The Hague on the 7th (local time) found that Keytruda SC infringes Halozyme’s European patent (EP 2,797,622) and imposed a blanket ban on its manufacture, sale, import and stockpiling in eight countries: Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands.
Following an interim injunction issued by the Munich Regional Court in Germany last December, the expedited proceedings on the merits have brought the number of European countries where Keytruda SC sales are blocked to nine.
The market and the company view the practical impact as limited, given that the eight countries where sales are banned account for only 6% to 8% of total Keytruda sales and the transition to the SC formulation is still in its early stages.
However, the substance of the case goes beyond the regional share of sales. The Hague court found that five of the 15 amino acid substitutions in ALT-B4’s core design structure (I309N, M310T, K314E, L317Q and L318A) fall directly within the scope of Halozyme’s patent claims.
The court also concluded that ALT-B4 fully infringes the structural and functional scope of Halozyme’s patent, citing residual activity testing in a phenol environment as evidence that ALT-B4 meets the functional requirement of greater phenol stability than the natural form.
As a result, Alteogen’s longstanding platform argument that ALT-B4 fully circumvented Halozyme’s earlier patent was rejected under the European judicial system. The court also rejected MSD’s argument that there was no infringement because the finished Keytruda SC product does not contain a phenolic preservative.
The court broadly interpreted the patent as a product claim covering the modified hyaluronidase enzyme itself. With a cross-border injunction issued against MSD BV, the Dutch entity that serves as MSD’s European marketing authorization holder, finished-product manufacturing and supply chain operations across Europe now face a bottleneck.
The ruling also signals potential disruption to the timing of sales milestones and running royalty payments, a core part of Alteogen’s revenue model. Alteogen is set to receive up to $1 billion in milestone payments from MSD and royalties in the 2% range on subsequent sales.
However, this depends on smooth commercialization and accumulated sales in major global markets. Keytruda SC generated $590 million in sales in the first half of this year and is expanding primarily in North America, but blocked sales in key European markets such as France and Italy could push back milestone timing and annual royalty estimates.
The ruling could pose a potential risk not only to Keytruda but also to other global licensing pipelines Alteogen is pursuing. Alteogen has pursued ALT-B4-based collaborations with more than 10 global pharmaceutical companies, including Daiichi Sankyo for Enhertu, Sanofi for Dupixent and GSK for Jemperli.
Because the European court identified the amino acid sequence and functional properties of the ALT-B4 protein itself as falling within the scope of Halozyme’s patent, other SC pipelines using the same enzyme as a drug-delivery vehicle could also face the legal risk of similar patent litigation when entering the European market.
There is room for counterarguments. The U.S. Patent Trial and Appeal Board (PTAB) has issued successive decisions invalidating key claims of Halozyme’s patent, while in the United Kingdom, Halozyme itself agreed to the patent’s revocation, leaving rulings divided across jurisdictions. MSD has also said it will appeal immediately and is continuing to pursue patent invalidation proceedings in courts across Europe.
However, invalidity proceedings in individual European countries and appellate hearings can take considerable time. If the court maintains its position at the German appeal hearing on the interim injunction scheduled for Nov. 19, legal uncertainty could persist even longer.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Charles River Acquires Two Frontage Bioanalytical Laboratories for $470 Million

Sanofi-Backed Windward Raises $225 Million in IPO to Develop Respiratory Drugs From China

PharmaResearch Reports Third-Quarter Operating Profit of KRW 186.4 Billion, Up 14.7% Year Over Year

Hanmi Pharmaceutical’s Operating Profit Reaches ₩222.6 Billion in First Three Quarters, Up 27.5% Year Over Year

Kolon TissueGene Posts 73.3 Billion Won in Net Income Through Q3, Returns to Profit

BlueMtec Posts 5.5 Billion Won in Net Income Through Q3, Returning to Profit From a Year-Earlier Loss